FDA Expands Bladder Cancer Regimen - Top-Institutions - MDSpire

FDA Expands Bladder Cancer Regimen

KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.

  • By

  • Kathryn Wighton

  • July 10, 2026

  • 2 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    Mount Sinai Tisch Cancer Center
    Mount Sinai Tisch Cancer Center

    New York, NY

    Key Differentiators

    • Urology
    • Oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #3

    Englander Institute for Precision Medicine
    Englander Institute for Precision Medicine

    New York, NY

    Key Differentiators

    • Precision Medicine
    • Oncology

  • #4

    Weill Cornell Medicine
    Weill Cornell Medicine

    New York, NY

    Key Differentiators

    • Medicine
    • Oncology

  • #5

    Fox Chase Cancer Center
    Fox Chase Cancer Center

    Philadelphia, PA

    Key Differentiators

    • Oncology

Original Source(s)

FDA Expands Bladder Cancer Regimen

  • by Kathryn Wighton

  • July 10, 2026

Related Content

FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

Prehabilitation Program May Benefit Patients Undergoing CRC Surgery

Structured implementation increased participation and improved preoperative fitness, while postoperative complication and mortality rates remained similar across groups.

CT Use May Add to Future Cancer Burden

Researchers projected approximately 103,000 future cancers associated with computed tomography examinations performed in the US in 2023.